India Pesticides LimitedQ1 FY27 Results & Financial Update

Faced with intense competition from lower-priced Chinese agrochemical imports, IPL is leveraging R&D to optimize process conditions and engineering to lower overall project costs and enhance operational efficiencies.

To reduce single-molecule dependency (such as fluctuations seen in star products like Pretilachlor), IPL is introducing 3 new products in FY27, including a new domestic fungicide import-substitute at Sandila and a multipurpose herbicide plant at Hamirpur.

Sales of the key paddy herbicide Pretilachlor experienced soft demand due to deficient and erratic rainfall across the domestic market, causing delayed or lost agricultural sowing.

Maintains relationships across more than 35 countries, leveraging global regulatory compliance and off-patent technical manufacturing capabilities to serve international agrochemical players.

Hamirpur facility development is advancing as planned with 2 out of 10 blocks currently operational. Management targets INR 50 crores to INR 60 crores in revenue from Hamirpur for FY27, scaling toward INR 1,000 crores over 3 to 4 years upon installing 8 to 10 blocks.

Total annual capex is planned at around INR 100 crores combined across Sandila and Hamirpur (including INR 70 crores to INR 100 crores per year at Hamirpur and INR 25 crores to INR 30 crores at Sandila for add-up systems). Expansions are funded entirely through internal accruals without taking term loans.

Current company-wide capacity utilization stands at approximately 70%. A new domestic fungicide import-substitute product is being added at Sandila via minor balancing capex of INR 2 crores to INR 3 crores, targeting 2,000 tons of capacity out of an estimated domestic import market of 4,000 to 5,000 tons.

The 9.2% year-on-year revenue decline was driven by a volume decrease of approximately 13%, partially offset by a price realization improvement of around 4%.

Management expects sustainable EBITDA margins to normalize around 18% under better operating conditions, though near-term margins are guided closer to 15% to 16%.

The company maintains a strong balance sheet with a healthy cash balance of INR 59 crores as of June 30, 2026, and intends to fund all growth projects via internal accruals.

Inventory levels rose due to lower-than-expected Q1 sales after manufacturing goods in anticipation of strong demand, pushing inventory days from 170 days to around 200 days (expected to normalize back to 170 days by Q3). Receivable days remained stable at approximately 120 days.

Management anticipates lower single-digit top-line growth for the full year FY27, supported by expected business improvements in Q3 and Q4.

Reiterates a long-term revenue potential of at least INR 1,000 crores from the Sandila facility over the next four years across 5 blocks, and a matching INR 1,000 crores potential from the Hamirpur facility over 3 to 4 years across 8 to 10 blocks.

Overall manufacturing capacity utilization stands at approximately 70% across current facilities.

The new fungicide product being localized at Sandila targets a domestic import market of 4,000 to 5,000 tons annually, priced between INR 500 and INR 600 per kg.

The company plans to introduce 3 new products/molecules in FY27, including the recently added fungicide, an additional herbicide at Sandila, and products from the Hamirpur multipurpose plant.

Demand for key herbicide Pretilachlor was subdued during the quarter due to deficient monsoon rains affecting paddy cultivation across the country.

Development at the Hamirpur facility is proceeding as planned, with 2 out of 10 blocks currently operational. The facility is expected to contribute INR 50 crores to INR 60 crores in revenue in FY27, scaling toward INR 1,000 crores over 3 to 4 years as 8 to 10 blocks are established.

The company is setting up manufacturing for an imported fungicide product currently dominated by Chinese imports, with a small balancing capex of INR 2 crores to INR 3 crores at the Sandila facility to produce ~2,000 tons out of India's total 4,000 to 5,000 tons of imports.

The 9.2% year-on-year revenue decline comprised approximately a 13% volume decline offset by a 4% rise in pricing.

Management expects sustainable EBITDA margins to normalize around 18% over the long term as geopolitical and market conditions improve, while guiding for 15.5% to 16% in the near term.

Inventory days increased due to lower-than-anticipated sales in June after manufacturing in anticipation of strong demand; inventory days are expected to decline from ~200 days back to ~170 days by Q3, while receivable days remain stable at approximately 120 days.

Management anticipates lower single-digit top-line growth for the full year FY27, backed by expected demand improvement in Q3 and Q4.

Hamirpur facility is projected to generate INR 50 crores to INR 60 crores in revenue during FY27.

Management highlighted that key execution priorities for the next two quarters include scaling the newly established import-substitute fungicide facility at Sandila and building out the multipurpose herbicide plant at Hamirpur, while using R&D process optimizations to counter low-priced Chinese imports.

CFO S.P. Gupta clarified that the INR 6 crores spike in job work expenses was incurred to convert raw materials into herbicide intermediates in anticipation of strong Q1 demand, which will be consumed during the upcoming peak season in Q3.

The new fungicide molecule is currently imported into India at 4,000 to 5,000 tons annually at prices between INR 500 and INR 600 per kg. IPL plans to manufacture up to 2,000 tons of capacity starting from basic industrial chemical stages at Sandila with minor balancing capex of INR 2 crores to INR 3 crores.

Sales for the newly EU-approved fungicide are expected to commence around November 2026 as European client companies complete local source-addition approvals, providing an estimated incremental annual revenue of INR 30 crores to INR 40 crores.

S.P. Gupta clarified that the INR 6 crores increase in job work charges represents conversion costs for raw materials into herbicide intermediates in anticipation of robust Q1 demand, which will be utilized during the upcoming Q3 season.

D.K. Jain noted that commercial sales from the EU Technical Equivalence approval are expected to commence around November onwards, as client companies require 1 to 2 months to register the new source.